Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach

9 episodes

1.00 program credits

1h 02m

Details

Episodes

Presenters

Overview
Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

Faculty:
James Burton, DM, FRCP
Professor of Renal Medicine
University Of Leicester
Leicester, United Kingdom

Dr. Burton has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: A. Menarini, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Diaverum

Javed Butler, MD, MPH, MBA
President, Baylor Scott and White Research Institute
Dallas, TX
Distinguished Professor of Medicine, University of Mississippi Medical Center
Jackson, MS

Dr. Butler has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Abbott, Adaptyx, American Regent, Amgen, AskBio, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillent, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultromic, Vera, Zoll
Speakers’ Bureaus: Boehringer Ingelheim-Lilly, Impulse Dynamics, Merck

Ellie Kelepouris, MD, FACP, FAHA
Professor of Clinical Medicine
Director of Outpatient Dialysis
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Dr. Kelepouris has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Bayer, Calliditas, CSL Vifor, Vera
Royalties: UpToDate

Patrick Rossignol, MD, PhD
Professor
Université de Lorraine
CHRU Nancy, France

Dr. Rossignol has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Bayer, Boehringer Ingelheim, CinCor, CSL Vifor, Idorsia, KBP, Novo Nordisk, Sanoﬁ, Servier

Reviewers/Content Planners/Authors:
Tim Person has no relevant relationships to disclose. 
Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 
Katie Sheridan, PhD, has no relevant relationships to disclose. 
Learning Objectives
Upon completion of this activity, learners should be better able to:
Review the latest guidelines on facilitating standard-of-care therapies for hyperkalemia in patients with chronic kidney disease (CKD) and heart failure (HF)
Analyze the clinical implications associated with hyperkalemia and suboptimal renin–angiotensin–aldosterone system (RAAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF)
Compare and contrast real-world efficacy and safety of oral potassium binders in patients with CKD and/or HF with/at risk of hyperkalemia
Develop evidence-based treatment strategies incorporating potassium binders to optimize the management of patients with CKD and HF with/at risk of hyperkalemia
Target Audience
This activity has been designed to meet the educational needs of nephrologists, HF specialists, cardiologists, and primary care physicians as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with hyperkalemia.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative (GLC)/AXIS Medical Education designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-086-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until September 24, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from CSL Vifor. 
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

 Reproduction Prohibited 

Reproduction of this materialis not permitted without written permission from the copyright owner. 
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 24/09/2025
Expiration Date: 24/09/2026